Coeptis Therapeutics Hldgs I
13F holders, Q2 2025 (June 30)9holders
1new positions
2sold out
$7.80avg. 13F price*
At the end of Q2 2025, 9 institutions reported holding Coeptis Therapeutics Hldgs I in their 13F filings, unchanged from Q1 2025. 1 opened new positions and 2 sold out. The largest holders were Yorkville Advisors Global, LP ($411K), Vanguard Group Inc. ($215K) and Geode Capital Management, LLC ($158K).
- Company
- Coeptis Therapeutics Hldgs I
- CUSIP
- 19207A207
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $8 |
| Exits | 2 | $5K |
All 13F filers, Q1 2025 → Q2 2025: 3,411 shares bought and 9,465 shares sold, net −6,054 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Yorkville Advisors Global, LP | 0.12% | — | 52,724 | $411K |
| Vanguard Group Inc. | 0.00% | Add +12.7% | 27,529 | $215K |
| Geode Capital Management, LLC | 0.00% | Add +1.6% | 20,280 | $158K |
| Steward Partners Investment Advisory, LLC | 0.00% | No change | 1,000 | $8K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -60.3% | 268 | $2K |
| UBS Group AG | 0.00% | Reduce -99.0% | 82 | $640 |
| Bank of America Corp. | 0.00% | Add +38.9% | 25 | $195 |
| Barclays PLC | 0.00% | No change | 3 | $23 |
| Raymond James Financial Inc. | 0.00% | New | 1 | $8 |
"% of holder's portfolio" is COEPTIS THERAPEUTICS HLDGS I's weight in each manager's 13F, not the share of Coeptis Therapeutics Hldgs I the manager owns.